{"nctId":"NCT01471574","briefTitle":"Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus","startDateStruct":{"date":"2011-12"},"conditions":["Hepatitis C, Genotype 1"],"count":549,"armGroups":[{"label":"Daclatsvir + Ribavirin + PEG-Interferon alfa-2a","type":"EXPERIMENTAL","interventionNames":["Drug: Daclatasvir","Drug: Ribavirin","Drug: PEG-Interferon alfa 2a"]}],"interventions":[{"name":"Daclatasvir","otherNames":["BMS-790052"]},{"name":"Ribavirin","otherNames":["Copegus®"]},{"name":"PEG-Interferon alfa 2a","otherNames":["Pegasys®","Pegylated interferon"]}],"eligibilityModule":{"eligibilityCriteria":"For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com\n\nKey Inclusion Criteria:\n\n* Males and females, 18 to 70 years of age\n* Hepatitis C virus (HCV) genotype 1a or 1b\n* HCV-treatment naive\n* HCV RNA \\>10,000 IU/mL at screening\n* HIV-1 infection (approximately 250 patients receiving highly active antiretroviral therapy \\[HAART\\], up to 50 patients not receiving HAART)\n* For patients receiving HAART, HIV RNA must be below \\<40 copies/mL at screening and must be \\<400 copies/ml for at least 6 months prior to screening\n\nKey Exclusion Criteria:\n\n* Patients receiving HAART who first initiated antiretroviral therapy within the last 6 months of Day 1\n* Patients receiving HAART who have changed their antiretroviral regimen due to safety or efficacy associated to HIV treatment within the last 3 months prior to Day 1. However, if changes are required to a patient's HAART regimen to meet the requirements of the protocol, these changes are allowed at the screening visit. The patient should wait a minimum of 1 month prior to Day 1 after a repeat of HIV viral load has been confirmed, \\<40 copies/ mL\n* Use of prohibited HAART regimens within 1 month of Day 1 and throughout the treatment period of the trial (patients receiving HAART who have changed their antiretroviral regimen to initiate any HCV treatment within 6 weeks prior to Day 1)\n* Laboratory values:\n\n  1. Neutrophil count \\<1500 cells/μL (\\<1200 cells/ μL for Blacks)\n  2. Platelet count \\<90,000 cells/μL\n  3. Hemoglobin ≤12 g/dL for females, hemoglobin ≤13 g/dL for males\n  4. Total bilirubin ≥34 μmol/L (or ≥2 mg/dL) unless a patient has a documented history of Gilbert's disease or antiretroviral regimen contains atazanavir\n  5. Alanine aminotransferase ≥5\\*upper limit of normal","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Sustained Virologic Response at Follow-up Week 12 (SVR12)","description":"SVR12 was defined as hepatitis C virus (HCV) values lower than the lower limit of quantitation, target detected or target not detected at follow-up Week 12. HCV RNA levels were measured by the Roche COBAS® TaqMan® HCV Test version 2.0 from the central laboratory. HAART=highly active antiretroviral therapy. SVR12 was defined as hepatitis C virus (HCV) values lower than the lower limit of quantitation, target detected or target not detected at follow-up Week 12. HCV RNA levels were measured by the Roche COBAS® TaqMan® HCV Test version 2.0 from the central laboratory. HAART=highly active antiretroviral therapy.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75","spread":null},{"groupId":"OG001","value":"71.8","spread":null},{"groupId":"OG002","value":"71.7","spread":null},{"groupId":"OG003","value":"73.3","spread":null},{"groupId":"OG004","value":"87.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved Hepatitis C Virus (HCV) RNA Levels Lower Than The Lower Limit of Quantitation (LLOQ), Target Detected (TD) or Target Not Detected (TND)","description":"Participants who achieved HCV RNA levels lower than the LLOQ i.e., 25 IU/ml, TD or TND. HCV RNA levels were measured by the Roche COBAS® TaqMan® HCV Test version 2.0 from the central laboratory. HAART=highly active antiretroviral therapy.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39.7","spread":null},{"groupId":"OG001","value":"41.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.5","spread":null},{"groupId":"OG001","value":"91.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82.7","spread":null},{"groupId":"OG001","value":"95.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84.1","spread":null},{"groupId":"OG001","value":"87.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84.1","spread":null},{"groupId":"OG001","value":"95.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.2","spread":null},{"groupId":"OG001","value":"91.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78.7","spread":null},{"groupId":"OG001","value":"91.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84.8","spread":null},{"groupId":"OG001","value":"95.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73.3","spread":null},{"groupId":"OG001","value":"87.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70.4","spread":null},{"groupId":"OG001","value":"83.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved Hepatitis C Virus (HCV) RNA Levels Lower Than the Lower Limit of Quantitation (LLOQ), Target Not Detected (TND)","description":"Participants who achieved HCV RNA levels lower than the LLOQ, TND. HCV RNA levels were measured by the Roche COBAS® TaqMan® HCV Test version 2.0 from the central laboratory. HAART=highly active antiretroviral therapy.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"16.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.9","spread":null},{"groupId":"OG001","value":"50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.3","spread":null},{"groupId":"OG001","value":"91.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.4","spread":null},{"groupId":"OG001","value":"87.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78","spread":null},{"groupId":"OG001","value":"95.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81.2","spread":null},{"groupId":"OG001","value":"91.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.4","spread":null},{"groupId":"OG001","value":"87.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84.8","spread":null},{"groupId":"OG001","value":"95.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73.3","spread":null},{"groupId":"OG001","value":"87.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70.4","spread":null},{"groupId":"OG001","value":"83.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Received Highly Active Antiretroviral Therapy (HAART), Maintained HIV RNA <40 Copies/mL, and Experienced Confirmed HIV RNA ≥400 Copies/mL","description":"Participants who received HAART, maintained HIV RNA \\<40 copies/mL, and experienced confirmed HIV RNA ≥ 400 copies/mL were determined.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.6","spread":null},{"groupId":"OG001","value":"89.7","spread":null},{"groupId":"OG002","value":"93.4","spread":null},{"groupId":"OG003","value":"90.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"2.6","spread":null},{"groupId":"OG002","value":"0.0","spread":null},{"groupId":"OG003","value":"0.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Sustained Virologic Response (SVR12) by rs12979860 Single Nucleotide Polymorphism (SNP) in the IL28B Gene","description":"Percentages calculated as number of responders/number who received treatment.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94.4","spread":null},{"groupId":"OG001","value":"92.9","spread":null},{"groupId":"OG002","value":"79.5","spread":null},{"groupId":"OG003","value":"87.6","spread":null},{"groupId":"OG004","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"66.7","spread":null},{"groupId":"OG001","value":"63.6","spread":null},{"groupId":"OG002","value":"70.0","spread":null},{"groupId":"OG003","value":"67.4","spread":null},{"groupId":"OG004","value":"93.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.2","spread":null},{"groupId":"OG001","value":"33.3","spread":null},{"groupId":"OG002","value":"58.3","spread":null},{"groupId":"OG003","value":"62.2","spread":null},{"groupId":"OG004","value":"50.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"60.0","spread":null},{"groupId":"OG003","value":"71.4","spread":null},{"groupId":"OG004","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Died and With Serious Adverse Event (SAEs), Grade 3 to 4 Adverse Events (AEs), and AEs Leading to Discontinuation","description":"Adverse event was defined as any new unfavorable symptom, sign, or disease or worsening of a pre-existing condition that does not necessarily have a causal relationship with treatment. SAE was defined as a medical event that at any dose resulted in death, persistent or significant disability/incapacity, or drug dependency/abuse; was life-threating, an important medical event, or a congenital anomaly/birth defect; or required prolonged hospitalization. HAART=highly active antiretroviral therapy.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"2","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"6","spread":null},{"groupId":"OG003","value":"24","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46","spread":null},{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"35","spread":null},{"groupId":"OG003","value":"93","spread":null},{"groupId":"OG004","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"6","spread":null},{"groupId":"OG003","value":"17","spread":null},{"groupId":"OG004","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":12,"n":132},"commonTop":["Fatigue","Neutropenia","Anaemia","Asthenia","Headache"]}}}